Skip to Content

Pfizer Inc PFE Stock Quote

| Rating as of


Last close prices updated as of Feb 03, 2023, 7:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 44.06
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Value
  • Day Range 43.88  –  44.39
  • Year Range 41.45  –  56.32
  • Market Cap 247.3226 Bil
  • Volume / Avg 631.0 /  21.1 Mil
  • Price / Sales 2.52
  • Price / Book 2.67
  • Forward Div Yield 3.72%
  • Trailing Div Yield 3.65%

Morningstar‘s Stock Analysis PFE

Currency in USD
PFE is Fairly Valued at a 8% Discount.
PFE is 3 at a 8% -8.

1-Star Price

> 64.80

5-Star Price

< 33.60

Economic Moat


Trend: Stable

Capital Allocation


Pfizer's Q4 Earnings Are Solid; Weaker-Than-Expected 2023 Guidance Is Not Overly Concerning

Damien Conover Sector Director

Analyst Note

| Damien Conover |

Pfizer reported solid fourth-quarter results but provided lower-than-expected guidance for 2023. We don’t expect any major changes to our Pfizer fair value estimate, and the stock looks undervalued, especially with the recent weak stock performance that doesn’t appear to be fully reflecting the firm’s long-term outlook.

The poor 2023 outlook is largely due to falling COVID-19 product sales (Comirnaty vaccine and Paxlovid treatment) along with heavy investments into research and development as well as marketing. While the magnitude of the investments is surprising, the investments should help Pfizer prepare for the major patent losses between 2025 and 2028 (including immunology drug Xeljanz, cardiology drug Eliquis, rare disease drug Vyndaqel, and cancer drugs Ibrance, Xtandi, and Inlyta, totaling close to $18 billion in 2022). While we expect some pressure over this period, Pfizer is preparing well to largely avoid any major earnings declines, which gives us confidence in its wide moat.

Pfizer’s 2023 guidance includes $13.5 billion in Comirnaty sales and $8 billion of Paxlovid sales, which seems reasonable, with higher prices partially offsetting high channel supply and falling demand. Importantly, Pfizer expects COVID-19 revenue to increase in 2024 and beyond. While 2024 COVID-19 product sales should benefit from lower supplies in the channel relative to 2023, we are skeptical that growth beyond 2024 will occur as the pandemic fades. If these products can grow over the long term, we believe there is further upside to our valuation.

Several recently launched drugs and pipeline drugs are poised to support long-term cash flows. The launch of the next generation pneumococcal vaccine Prevnar 20 is progressing well. We are also bullish on the outlook for migraine drug Nurtec (acquired through Biohaven). In the pipeline, Pfizer's RSV vaccine, cancer drug elranatamab, and immunology drugs Cibinqo, ritlecitinib, and etrasimod all look poised to become blockbusters.

Key Statistics PFE

Company Profile PFE

Business Description

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

235 East 42nd Street
New York, NY, 10017
Industry Drug Manufacturers - General
Employees 79,000

Related Articles PFE

FAQs for Pfizer Inc Stock

Yes. PFE has a forward dividend yield of 3.72%. See PFE’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

PFE’s market cap is 247.32 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

PFE’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

PFE’s price/sales is 2.52.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

PFE’s price/forward earnings is 10.41.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

PFE’s price/book is 2.67.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See PFE’s valuation ratios compared to the Market Index.

PFE’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare PFE’s historical performance against its industry peers and the overall market.